Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary‐like nuclear features

Jiang, Xiaoyin “Sara”; Harrison, Grant; Datto, Michael B.

doi:10.1002/cncy.21802

Cited by 69 publications

(86 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although lymph node metastasis in NIFTP is reported to be rare, we identified two such NIFTP cases. In both cases, the metastasis was to a single central lymph node, and the size of the metastatic focus was <2 mm.…”

Section: Methodsmentioning

confidence: 99%

Diagnostic value of HBME‐1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma

Cho

Kim

2018

Pathology International

View full text Add to dashboard Cite

Our aim is to explore differences in Hector Battifora mesothelial‐1 (HBME‐1), cytokeratin‐19 (CK19), Galectin‐3 (Gal‐3), and CD56 expression in infiltrative follicular variants of papillary carcinoma (IFVPTC) and encapsulated follicular variants of papillary carcinoma (EFVPTC) and to provide clues for distinguishing the two subtypes preoperatively. Tissue microarrays from 100 EFVPTC (45 non‐invasive follicular thyroid neoplasms with papillary‐like nuclear features (NIFTP) and 55 invasive EFVPTCs), 43 IFVPTCs, and 64 follicular neoplasms (FN) were immunostained with HBME‐1, CK19, Gal‐3, and CD56. Each case was scored 1 point for every positive result. Immunohistochemical expression was not significantly different in invasive EFVPTC and NIFTP, except for that of HBME‐1. HBME‐1, CK19, Gal‐3, and CD56 expression were significantly higher in IFVPTC than in EFVPTC. At the cutoff of 3 points, the score method had special diagnostic value for differentiating IFVPTC from EFVPTC and FN and for predicting lymph node metastasis. Scoring of immunohistochemistry results may be applied to core biopsy or cell blocks to assist ultrasonographic, cytologic and molecular tests in differentiating IFVPTC and EFVPTC preoperatively, possibly appropriately guiding EFVPTC preoperatively for limited operation or active surveillance.

show abstract

Section: Methodsmentioning

confidence: 99%

Diagnostic value of HBME‐1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma

Cho

Kim

2018

Pathology International

View full text Add to dashboard Cite

show abstract

“…These studies will also allow a reevaluation of the reproducibility and robustness of the diagnostic criteria for NIFTP. This need is highlighted by 2 recent studies reporting single cases diagnosed as NIFTP with regional lymph node metastasis 21, 23. The NIFTP diagnostic errors may occur in both follicular and papillary lineage directions.…”

Section: Introductionmentioning

confidence: 99%

AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State‐of‐the‐art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary‐like nuclear features

et al. 2018

View full text Add to dashboard Cite

The newly introduced pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary‐like nuclear features (NIFTP) will result in less bilateral thyroid surgery as well as deescalation in T4 suppressive and radioactive iodine treatment. Although, NIFTP is a nonmalignant lesion that has nuclear features of some papillary malignancies, the challenge for the surgeon is to identify a lesion as possibly NIFTP before the pathologic diagnosis. NIFTP, due to its reduction of overall rates of malignancy, will result in the initial surgical pendulum swinging toward lobectomy instead of initial total thyroidectomy. This American Head and Neck Society endocrine section consensus statement is intended to inform preoperative evaluation to attempt to identify those patients whose final pathology report may ultimately harbor NIFTP and can be offered a conservative surgical plan to assist in cost‐effective, optimal management of patients with NIFTP.

show abstract

“…Current data indicate the presence of mainly RAS mutations, along with PPARγ and THADA fusions [68]. However, some papers reported NIFTPs with the BRAF V600E mutation [69] or a coexistence of TERT promoter and RAS mutations [70]. Simultaneously, another paper emphasised the importance of tightening the classification criteria, since the BRAF V600E mutation has not been present in NIFTP cases, in which papillary structures were absent [69].…”

Section: Phenotypic and Molecular Heterogeneity Of Tc Subtypesmentioning

confidence: 99%

Heterogeneity of Thyroid Cancer

et al. 2018

View full text Add to dashboard Cite

There are 5 main histological types of thyroid cancers (TCs): papillary, follicular (also known as differentiated), poorly differentiated, anaplastic (the most aggressive form), and medullary TC, and only the latter arises from thyroid C cells. These different forms of TCs show significant variability, both among and within tumours. This great variation is particularly notable among the first 4 types, which all originate from thyroid follicular cells. Importantly, this heterogeneity is not limited to histopathological diversity only but is also manifested as variation in several genetic and/or epigenetic alterations, the numbers of interactions between the tumour and surrounding microenvironment, and interpatient differences, for example. All these factors contribute to the great complexity in the development of a tumour from cancer cells. In the present review, we summarise the knowledge accumulated about the heterogeneity of TCs. Further research in this direction should help to gain a better understanding of the underlying mechanisms contributing to the development and diversity of TCs, paving the way toward more effective treatment strategies.

show abstract

Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary‐like nuclear features

Cited by 69 publications

References 29 publications

Diagnostic value of HBME‐1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma

Diagnostic value of HBME‐1, CK19, Galectin 3, and CD56 in the subtypes of follicular variant of papillary thyroid carcinoma

AHNS Series: Do you know your guidelines? AHNS Endocrine Section Consensus Statement: State‐of‐the‐art thyroid surgical recommendations in the era of noninvasive follicular thyroid neoplasm with papillary‐like nuclear features

Heterogeneity of Thyroid Cancer

Contact Info

Product

Resources

About